ライフサイエンスコーパス: pegfilgrastim

1 cular mass of 40074.64 Da was determined for pegfilgrastim.

2 for the detection of methionine oxidation in pegfilgrastim.

3 and active in CRPC and requires dosing with pegfilgrastim.

4 the combination of docetaxel, lapatinib, and pegfilgrastim.

5 taneous injection of either normal saline or pegfilgrastim.

6 A single subcutaneous injection of pegfilgrastim 100 micro g/kg produced a sustained serum

7 ) for six cycles with scheduled subcutaneous pegfilgrastim 6 mg on day 2 of each cycle.

8 00 mg/m(2)) for 4 cycles every 2 weeks (with pegfilgrastim 6 mg on day 2) followed by paclitaxel (80

9 Patients received pegfilgrastim 6 mg subcutaneous (SQ) on day 2 of each cy

10 Pegfilgrastim 6 mg subcutaneous injection was administer

11 g/m2 and ixabepilone 35 mg/m2 every 21 days, pegfilgrastim 6 mg subcutaneously day 2, and continuous

12 were randomly assigned to either placebo or pegfilgrastim 6 mg subcutaneously on day 2 of each 21-da

13 d by P (175 mg/m(2)) x 4 every 2-weekly with pegfilgrastim (6 mg on day 2) + T x1 year.

14 of this study was to evaluate the effects of pegfilgrastim, a long-acting granulocyte colony-stimulat

15 lute quantification of oxidation variants of pegfilgrastim, a poly(ethylene glycol) modified recombin

16 s of dose-dense chemotherapy and the ease of pegfilgrastim administration.

17 ion kits have different capacities to detect pegfilgrastim aggregates that rapidly form in vitro in p

18 % prediction interval, -95.2% to -54.0%) for pegfilgrastim and -62.3% (95% prediction interval, -73.4

19 Pegfilgrastim and darbepoetin alfa are effective and saf

20 The incidence of grade 4 neutropenia in the pegfilgrastim and filgrastim groups was 69% and 68%, res

21 Results Pegfilgrastim and filgrastim were similar for all effica

22 h the largest price reductions observed with pegfilgrastim and infliximab, with 5-year price reductio

23 roblem that may result in discontinuation of pegfilgrastim and lead to less effective chemotherapy do

24 time was similar between patients receiving pegfilgrastim and patients who initially received placeb

25 famide (10 g/m(2) over 4 days with mesna and pegfilgrastim) as first-line treatment.

26 CONCLUSION A single dose of pegfilgrastim at 100 microg/kg administered once per che

27 Finally, an expired pegfilgrastim batch was analyzed as a a real biopharmace

28 The protocol was amended to include pegfilgrastim because of dose-limiting toxicity (neutrop

29 One challenge to overcome in pegfilgrastim biosimilar development is establishing pha

30 ony stimulating factor (PEGylated rhG-CSF or pegfilgrastim), by electrospray ionization-mass spectrom

31 The stability patterns of pegfilgrastim closely match the stability patterns of fi

32 Patients receiving pegfilgrastim, compared with patients receiving placebo,

33 g studies involving the measurement of serum pegfilgrastim concentrations.

34 6:1 randomization ratio to receive a single pegfilgrastim dose of 100 microg/kg (n = 38) or daily fi

35 protracted neutropenia and had higher median pegfilgrastim exposure than older children.

36 receiving 1 dose of docetaxel and adjunctive pegfilgrastim, follow-up (18)F-FDG PET/CT (scan 2).

37 ible and received three cycles of AMVAC with pegfilgrastim followed by radical cystectomy with lymph

38 standardized uptake value) was higher in the pegfilgrastim group 1 d after injection (mean +/- SD, 8.

39 bility in the stability and detectability of pegfilgrastim in human sera is also observed.

40 ile neutropenia were converted to open-label pegfilgrastim in subsequent cycles.

41 Interventions for pegfilgrastim-induced bone pain are needed.

42 Pegfilgrastim-induced bone pain is a significant clinica

43 ve in reducing the incidence and severity of pegfilgrastim-induced bone pain.

44 t incidence, severity, or ability to prevent pegfilgrastim-induced bone pain.

45 nd pharmacokinetics of a single subcutaneous pegfilgrastim injection with daily subcutaneous filgrast

46 human granulocyte colony stimulating factor (pegfilgrastim) is used clinically to accelerate immune r

47 Pegfilgrastim levels display marked subject variability

48 In both the animal model and humans, pegfilgrastim markedly increased bone marrow uptake of (

49 ions in (18)F-FDG biodistribution induced by pegfilgrastim must be considered when one is evaluating

50 eight patients received placebo (n = 465) or pegfilgrastim (n = 463).

51 ndard epirubicin) or every 2 weeks with 6 mg pegfilgrastim on day 2 of each cycle (accelerated epirub

52 ndard epirubicin) or every 2 weeks with 6 mg pegfilgrastim on day 2 of each cycle (accelerated epirub

53 All patients received pegfilgrastim on day 2 of each cycle and aspirin prophyl

54 , the highest dose levels were repeated with pegfilgrastim on day 2 of each cycle.

55 ications, corticosteroids, immunostimulants (pegfilgrastim), opioids, analgesics, anxiolytics, antide

56 nts randomly assigned to receive one dose of pegfilgrastim or daily filgrastim after chemotherapy.

57 A single injection of pegfilgrastim per chemotherapy cycle provided neutrophil

58 between two treatment strategies of primary pegfilgrastim prophylaxis.

59 evacizumab, epoetin, filgrastim, infliximab, pegfilgrastim, rituximab, and trastuzumab).

60 f filgrastim, consistent with a key role for pegfilgrastim's G-CSF moiety in driving formation of ina

61 Once-per-cycle administration of pegfilgrastim simplifies the management of neutropenia a

62 Pegfilgrastim stressed with 1.0% hydrogen peroxide serve

63 ficacy and safety of neoadjuvant ddMVAC with pegfilgrastim support in muscle-invasive urothelial canc

64 ffects of a single subcutaneous injection of pegfilgrastim (sustained-duration filgrastim) 100 micro

65 We evaluated the efficacy of pegfilgrastim to reduce the incidence of febrile neutrop

66 C-CSF use increased from 13.2% to 67.9%, and pegfilgrastim use increased from 4.1% to 83.6%.

67 nefit from dose-dense chemotherapy, limiting pegfilgrastim use would combat the increasing costs of c

68 dose level for lapatinib and docetaxel with pegfilgrastim was 1,250 mg (once daily) and 75 mg/m(2) (

69 In 2002, pegfilgrastim was approved by the US Food and Drug Admin

70 Pegfilgrastim was generally well tolerated and safe, and

71 e maximum tolerated dose in combination with pegfilgrastim was not exceeded.

72 Pegfilgrastim was safe and well tolerated in this patien

73 combination of docetaxel and lapatinib with pegfilgrastim was well tolerated.

74 First and subsequent cycle use of pegfilgrastim with a moderately myelosuppressive chemoth